Is the pattern of high fasting insulin, high triglycerides, low HDL, and low SHBG indicative of hepatic insulin resistance?

An evidence-based assessment of the biomarker pattern consisting of high fasting insulin, elevated triglycerides, low HDL cholesterol, and low sex hormone-binding globulin (SHBG) reveals a highly coordinated metabolic signature.

Mechanistic explanations

• The TG-HDL axis and VLDL overproduction: Systemic and hepatic insulin resistance drive selective hyperinsulinemia, which continuously stimulates hepatic de novo lipogenesis (DNL). This process converts carbohydrates into fatty acids, leading to lipid accumulation within the liver and the overproduction of large, triglyceride-rich very-low-density lipoprotein (VLDL) particles. These particles undergo rapid remodeling by cholesteryl ester transfer protein (CETP) and hepatic lipase, resulting in elevated serum triglycerides and the accelerated clearance of HDL cholesterol.
• Transcriptional downregulation of SHBG: The liver is the exclusive site of SHBG synthesis. Accumulation of liver fat and associated subclinical hepatic inflammation suppress the activity of hepatocyte nuclear factor 4-alpha ($HNF4\alpha$), which is the primary transcription factor required for the expression of the SHBG gene. Consequently, circulating SHBG levels drop, serving as a direct molecular surrogate for hepatic fat accumulation and hepatic insulin resistance.

Clinical evidence and implications

• Marker of metabolic risk: Extensive epidemiological and clinical data demonstrate that the combination of high triglycerides, low HDL, and suppressed SHBG is a robust predictor of type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD/MASLD).
• Synergistic diagnostic value: In a young female cohort, this pattern is highly sensitive. Low SHBG is not merely a marker of androgen status but acts as a highly sensitive metabolic sensor of liver fat. When clustered with hyperinsulinemia and dyslipidemia, it provides strong diagnostic utility for identifying early-stage hepatic insulin resistance before the onset of overt hyperglycemia.

Bottom line

A biomarker pattern of high fasting insulin, elevated triglycerides, low HDL, and low SHBG is strongly supported by scientific evidence as a reliable metabolic signature of systemic insulin resistance, specifically reflecting hepatic insulin resistance, hepatic de novo lipogenesis, and early-stage liver fat accumulation.